GLP1R and Obesity: The nontargeted antiobesity medications (AOM), such as naltrexone-bupropion and glucagon-like peptide-1 (GLP-1) receptor agonists, have been approved for obesity treatment in general, whereas the targeted pharmacotherapeutical agent, setmelanotide, has only been approved for specific genetic obesity disorders.